Yes management bungled this. My guess is they saw the favorable response in the very first pt enrolled who had prologned SD w DLBCL who relapsed post transplant where average survival is only around 3 months then a PR at that same low dose and they thought they had a home run on their hands, which obviously was not the case when data from later cohorts came in
TRIL - a single investor slated to take up the offering
I didn't read this as a single investor willing to take the whole offering, just that an existing one would participate and it could take them over 10%, at which point they would get a seat on the board.
I pursued the filings, but couldn't see that this happened or the existing shareholder was identified. Anybody know whether it happened and if so, who it was?
News 
Market Data 
Discover 
